F
Francis Lévi
Researcher at University of Warwick
Publications - 275
Citations - 18199
Francis Lévi is an academic researcher from University of Warwick. The author has contributed to research in topics: Circadian rhythm & Colorectal cancer. The author has an hindex of 53, co-authored 261 publications receiving 16652 citations. Previous affiliations of Francis Lévi include Université Paris-Saclay & Coventry Health Care.
Papers
More filters
Journal ArticleDOI
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh,François Ghiringhelli,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Michel Obeid,Michel Obeid,Michel Obeid,Carla Ortiz,Carla Ortiz,Carla Ortiz,Alfredo Criollo,Alfredo Criollo,Alfredo Criollo,Grégoire Mignot,Grégoire Mignot,Grégoire Mignot,M. Chiara Maiuri,Evelyn Ullrich,Evelyn Ullrich,Evelyn Ullrich,Patrick Saulnier,Huan Yang,Sebastian Amigorena,Bernard Ryffel,Franck J. Barrat,Paul Saftig,Francis Lévi,Francis Lévi,Rosette Lidereau,Catherine Noguès,Jean-Paul Mira,Agnès Chompret,Virginie Joulin,Françoise Clavel-Chapelon,Jean Bourhis,Fabrice Andre,Suzette Delaloge,T. Tursz,Guido Kroemer,Guido Kroemer,Guido Kroemer,Laurence Zitvogel +42 more
TL;DR: A previously unrecognized pathway for the activation of tumor antigen–specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs) is described.
Journal ArticleDOI
Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
René Adam,Valérie Delvart,Gérard Pascal,Adrian Valeanu,Denis Castaing,Daniel Azoulay,Sylvie Giacchetti,Bernard Paule,Francis Kunstlinger,Odile Ghémard,Francis Lévi,Henri Bismuth +11 more
TL;DR: Modern chemotherapy allows 12.5% of patients with unresectable CRLM to be rescued by liver surgery, with a wide use of repeat hepatectomies and extrahepatic resections, and four preoperative risk factors could select the patients most likely to benefit from this strategy.
Journal ArticleDOI
Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer
Sylvie Giacchetti,B. Perpoint,Rachid Zidani,N. Le Bail,R. Faggiuolo,Christian Focan,Philippe Chollet,J.F. Llory,Y. Letourneau,Bruno Coudert,F. Bertheaut-Cvitkovic,D. Larregain-Fournier,A. Le Rol,Stephen D. Walter,Rosalyn M. Adam,J.L. Misset,Francis Lévi +16 more
TL;DR: By chronomodulating 5-FU-LV, the authors were able to add l-OHP without compromising dose-intensities and significantly improved the antitumor efficacy of this regimen.
Journal ArticleDOI
Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
René Adam,Gérard Pascal,Denis Castaing,Daniel Azoulay,Valérie Delvart,Bernard Paule,Francis Lévi,Henri Bismuth +7 more
TL;DR: Liver resection is able to offer long-term survival to patients with multiple colorectal metastases provided that the metastatic disease is controlled by chemotherapy prior to surgery.
Journal ArticleDOI
Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.
Henry Bismuth,René Adam,Francis Lévi,Christian Farabos,Fabio Waechter,Denis Castaing,Pietro Majno,Luc Engerran +7 more
TL;DR: Liver resection may be achieved in some previously unresectable patients with the help of an effective chemotherapy, and the benefit in survival seems comparable to that obtained with primary liver resection.